MMTZFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as RLFTY
MindMaze Therapeutics Holding SA
Financials through fiscal 2023, year ended Dec 31, 2023Last filing: 20-F on Apr 30, 2024
$0.19−0.00 (-0.22%)
Close on Oct 19, 2026
MindMaze Therapeutics Holding SA revenue by segment
By business segment
By product or service
| Revenue | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|
| Product sales [member] | CHF 4.26M | CHF 2.53M | CHF 1.31M | 67.3% | +68.6% |
| Royalties [member] | CHF 1.41M | CHF 2.48M | CHF 1.27M | 22.3% | -43.2% |
| Revenue from research and development services [member] | CHF 347.00K | CHF 694.00K | – | 5.5% | -50.0% |
| Licensing fees [member] | CHF 19.00K | CHF 380.00K | – | 0.3% | -95.0% |
| Revenue from research development services [member] | – | CHF 694.00K | CHF 459.00K | – | – |
| License fees [member] | – | CHF 380.00K | CHF 289.00K | – | – |
By region
| Revenue | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|
| Europe (excluding Switzerland) [member] | CHF 2.89M | CHF 2.41M | CHF 1.12M | 45.6% | +19.7% |
| North America [member] | CHF 1.41M | CHF 1.70M | CHF 835.00K | 22.2% | -17.2% |
| Rest of the world [member] | CHF 1.33M | CHF 1.17M | CHF 844.00K | 21.0% | +13.4% |
| Switzerland | CHF 414.00K | CHF 800.00K | CHF 527.00K | 6.5% | -48.3% |
From the segment and revenue-disaggregation notes of MindMaze Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.